Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2026)
13 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 20, 2026
Slide 1: 2026 Annual General Meeting – Chair's Address
ASX Release 20 November 2026 ASX code: PIQ For personal use only 2026 Annual General Meeting Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to present the Chair’s Address and Company Presentation to be prese
Slide 2: Chair's Address (continued)
Scientific innovation remains essential to our future. Our commercial focus gives that work a clear purpose: developing useful tests, protecting the technology behind them and building the evidence clinicians and payers need. Our immediate priority is to realise the potential of the core portfolio.
Slide 3: CEO and Managing Director's Address
CEO and Managing Director’s Address For personal use only Introduction Thank you, James, and good morning. Since joining Proteomics International in January, my focus has been to turn our scientific achievements into commercial success. Promarker D and Promarker Eso are now commercially available ac
Slide 4: Distribution Healius Partnership
Distribution Healius Partnership Promarker D and Promarker Eso are now commercially available nationally. Controlled market For personal use only release began in Western Australia and the Northern Territory in September, followed by national rollout on 26 October 2026. Healius gives us national rea
Slide 5: Our Team
Our Team I would like to thank our people for the work that has brought us to this point. Their scientific For personal use only expertise, commitment to quality and commercial focus, have supported validation, laboratory improvements and the Australian launch. I also thank the Board for its guidanc
Slide 6: Annual General Meeting: Disciplined Path to Commercial Success
Proteomics International Laboratories Ltd rsonal use only Annual General Meeting Disciplined Path to Commercial Success 20 November 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Slide 7: Disclaimer
Disclaimer rsonal use only This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associa
Slide 8: Execution Plan – Achievements to Date
Execution Plan – Achievements to Date rsonal use only We have built a strong foundation for commercial success. RESET – FY26 H2 ACCESS – FY27 H1 Discontinued the DTC business model Appointed Healius as our Australian Engaged with potential distribution partners in distribution partner Australi
Slide 9: Product Innovation – Promarker Portfolio
Product Innovation – Promarker Portfolio rsonal use only Our portfolio of three prognostic and diagnostic tests target specific clinical areas of unmet need. Our priority is to commercialise these tests before developing new tests for other medical conditions. Promarker D Promarker Eso Promarker End
Slide 10: Distribution – Healius Partnership
Distribution – Healius Partnership rsonal use only We have appointed Healius as our national distribution partner in Australia. Healius provides market access through its collection network and referrer relationships, and Proteomics delivers testing and clinical reporting. Strategic Rationale Proteo
Slide 11: Strategic Roadmap – Immediate Focus
Strategic Roadmap – Immediate Focus rsonal use only Our strategic roadmap outlines our 3 year plan focused on commercialisation, fostering innovation, scaling processes and infrastructure, and enhancing our capabilities to achieve sustainable long term value. ADVANCE – FY27 H2 ACCELERATE – FY28 ACHI
Slide 12: Our Team
Our Team rsonal use only A capable and committed team, driven to deliver innovation and commercial success. 6
Slide 13: Thank You
Proteomics International Laboratories Ltd rsonal use only Thank You ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia
Proteomics International Laboratories — Shareholder Meeting (November 2026) on 6ix